Bristol Myers Squibb Company’s melanoma drug Opdualag (nivolumab plus relatlimab) has received a positive reimbursement opinion from England’s health technology assessment (HTA) body, NICE, less than two weeks after the drug was authorized for use by the medicines regulator, the MHRA.
The authorization was granted on 28 December after Opdualag was assessed through the Project Orbis initiative, an international regulatory framework...







